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Abstract
AIM: To characterize the bifidobacterial microbiota 
of the colonic mucosa in patients with colon cancer, 
infl ammatory bowel disease or diverticulitis.
METHODS: A sample of the distal colonic mucosa 
was taken during surgery from a total of 34 patients, 
twenty-one with diagnosed colorectal cancer, nine 
with diverticulitis and four with inflammatory bowel 
disease, requiring surgery for their condition. Bacterial 
DNA was extracted from the resected mucosal samples 
and bifidobacterial mucosa-associated microbiota was 
qualitatively and quantitatively determined by means of 
qualitative and quantitative PCR.
RESULTS: Bifidobacteria were found in 100% of the 
samples from patients with diverticulitis or IBD and 
a 76% of those suffering colon cancer. The species 
B. longum and B. bif idum  were the most widely 
found, followed by B. animalis , B. catenulatum and B. 
adolescentis . B. breve , B. dentium and B. angulatum 
were not detected in any sample. A signifi cantly higher 
occurrence of B. longum was observed in patients 
with diverticulitis than in those with colon cancer or 
IBD (100%, 62% and 75%, respectively, P  < 0.05). 
Similar results were obtained for B. animalis  (56%, 0% 
and 25%, P  < 0.05), while B. adolescentis  was only 
found in the mucosa from patients with colon cancer 
(5 out of 21, 24%). At the quantitative level, patients 
with colon cancer or IBD showed lower counts of total 
Bifi dobacterium (4.94 and 5.91 vs  6.96 log Cells/sample, 
respectively, P  < 0.05) and of the species B. longum (4.05 
and 4.79 vs  6.76, P  < 0.05) than those with diverticulitis.
CONCLUSION: Aberrancies in mucosa associated 
microbiota are present in different intestinal diseases. 
This may indicate a role of the microbiota in the 
pathogenesis of these diseases.
© 2007 WJG. All rights reserved.
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INTRODUCTION
The microbiota present in the human gastrointestinal 
tract has a significant influence on our health and well-
being. Different bacterial groups and levels are found 
throughout the gastrointestinal tract from mouth to colon. 
The stomach and the upper bowel are sparsely populated 
regions (103-104 CFU/g contents) while the colon is 
heavily populated (1011-1012 CFU/g contents). In the 
large intestine, genera such as Bacteriodes, Bifidobacterium, 
Eubacterium, Clostridium, Fusobacterium and Ruminococcus are 
usually found. This intestinal microbiota provides the most 
important contact with the environment for the host and a 
barrier against harmful food components and pathogenic 
bacteria[1,2]. The microbiota has also been shown to have a 
direct impact on the morphology of  the gut[3] and it plays 
an important role in the intestinal immuno-physiological 
regulation. A healthy microbiota can thus be defi ned as the 
normal individual microbiota which both preserves and 
promotes well-being and absence of  disease, especially in 
the gastrointestinal tract, but also beyond[4].
Major dysfunctions of  the gastrointestinal tract are 
thought to be related to disturbances or aberrancies of  
the intestinal microbiota[5]. Such aberrancies have been 
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identifi ed in atopic disease[6], rheumatoid arthritis[7], juvenile 
chronic arthritis[8], ankylosing spondylitis[9], irritable 
bowel syndrome (IBS)[10,11], inflammatory bowel disease 
(IBD)[12,13], colon cancer[14] and diverticulitis patients[15]. 
Specifically, aberrancies in bifidobacterial microbiota, 
including decreased numbers or an atypical composition 
have been identifi ed in some of  these diseases including 
atopic disease[6,16], IBS[11] or IBD[12,17,18]. Many diseases and 
their prevention can thus be linked to the microbiota in 
the gut. Demonstration of  this has stimulated research on 
the composition and function of  the microbiota. 
Microbiota development and characterization in 
the human host still rests largely on culture-dependent 
methods. These convent ional methods have low 
sensitivity and they are time consuming and biased due 
to the recovery of  only the culturable species or strains. 
These facts can lead to overestimation of  some species 
and underestimation of  others. Thus, during the last 
decade, developments in molecular biology have led to 
the application of  fast and reliable alternative culture-
independent methods[19].
Mucosal surfaces are the major sites of  contact with 
external agents including the members of  the intestinal 
microbiota. However, our knowledge on gut microbiota 
is mainly based in the assessment of  faeces and therefore 
hindered by the fact that the microbes found will mainly 
represent the microbiota in the lumen of  the sigmoid 
colon, while the composition of  the intestinal microbiota 
may differ between the lumen and the mucosa[20]. For 
more accurate information on the population elsewhere 
in the intestine, samples should preferably be taken by 
endoscopies or during surgery. 
Taking into account the possible role of  intestinal 
microbiota in the aetiology of  different intestinal diseases, 
culture-independent studies are needed to elucidate 
changes in the microbiota of  the intestinal mucosa. In 
this study we characterized the bifi dobacterial microbiota 
of  the colonic mucosa in patients with colon cancer, 
diverticulitis or IBD. The bifidobacterial microbiota 
was used as an indicator of  alterations in the mucosal 
colonisation pattern. For this purpose the mucosal 
Bifi dobacterium levels and composition were determined by 
means of  quantitative and qualitative PCR.
MATERIALS AND METHODS
Patients and samples
A total of  34 patients, twenty-one with diagnosed colorectal 
cancer, nine with diverticulitis and four with IBD requiring 
surgery for their condition were explained the study and 
the subjects gave informed consent for a sample taken 
during surgery for research purposes. The study protocol 
was approved by the Joint Committee of  Ethics for the 
University of  Turku and Turku University Hospital.
DNA extraction
The resected mucosal biopsies (area = 0.785 cm2) from 
the distal colon of  patients were cut into small pieces, 
resuspended in 1.4 mL of  buffer ASL (QIAamp DNA 
stool Mini kit, Qiagen, Hilden, Germany), vortexed 
thoroughly and used for the DNA extraction by using the 
QIAamp DNA stool Mini kit following the manufacturer’s 
instructions for gram-positive bacteria. DNA extracts were 
stored at -20℃ until its use.
Qualitative PCR
For the characterization of  the bifi dobacterial microbiota, 
previously described PCR primers targeting total members 
of  the genus[21] and different Bifidobacterium species or 
groups[22], including B. adolescentis, B. angulatum, B. animalis 
group (B. animalis ssp. animalis and B. animalis ssp. lactis), 
B. bifidum, B breve, B. catenulatum group (B. catenulatum 
and B. pseudocatenulatum), B. dentium and B. longum group 
(B. longum biotype longum, B. longum biotype infantis) were 
used as described by Rinne and coworkers[22]. All of  the 
oligonucleotides used were purchased from Thermo 
Electron Corporation (Thermo Biosciences, Ulm, 
Germany). Amplification of  the DNA was performed 
using a PCR iCycler apparatus (Bio-Rad, Espoo, Finland). 
The total volume of  each PCR was 50 μL, employing 4 μL 
of  DNA extract as a template. Amplifi ed products were 
subjected to gel electrophoresis in 1% agarose gels and 
were visualized by ethidium bromide staining. DNA 
extracts were analyzed in two independent PCR runs.
Quantitative PCR
Total bifi dobacterial levels as well as the levels of  the most 
frequently found species (B. longum group and B. bifi dum) 
were determined by means of  quantitative PCR. Previously 
reported oligonucleotides and methodologies were used to 
determine the total levels of  bifi dobacteria[21] and those of  
B. longum and B. bifi dum[23]. For standard curves, different 
dilutions of  microbial cultures from the appropriate 
bifi dobacterial strains (B. infantis and B. longum or B. bifi dum; 
cell numbers ranging from 1 × 104 to 4 × 109 cells/mL) 
were used for the DNA extraction with the QIAamp DNA 
stool Mini Kit (Qiagen). Samples (2 μL) were analyzed in 
50 μL amplifi cation reactions by using the procedures and 
conditions previously described[21,23]. The numbers of  cells 
of  Bifi dobacterium in the fecal samples were determined by 
comparing the Ct values obtained to the standard curve. 
DNA extracts from the different samples were analyzed by 
duplicate in at least two independent PCR runs.
Statistical analyses
Statistical analysis was carried out using the SPSS 12.0 
software (SPSS Inc., Chicago, IL, USA). χ2 test was used 
to compare proportions between groups. Data on bacterial 
levels were subjected to one-way ANOVA using the disease 
group as factor with three categories; colorectal cancer, 
diverticulitis and IBD. The least signifi cant difference (LSD) 
test was used for comparison of  means.
RESULTS
Qualitative Bifi dobacterium composition
The occurrence of  the genus Bifidobacterium and the 
different bifi dobacterial species or groups in the mucosal 
samples analysed are shown in Figure 1. Members of  
the genus Bifidobacterium were present in all the samples 
corresponding to patients with diverticulitis or IBD but 
only in a 76% of  the mucosa samples from colorectal 
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cancer patients (n.s. differences). 
B. longum group followed by B. bif idum were the 
species most widely found while B. breve, B. dentium and B. 
angulatum were not detected in any sample. A signifi cantly 
higher occurrence of  B. longum was observed in patients 
with diverticulitis (Figure 1) than in those suffering a 
different disease (100% vs 62% in colorectal cancer and 
75% in IBD patients, P < 0.05). Interestingly, a signifi cantly 
higher occurrence of  B. animalis was also found in these 
patients (56%) than in those suffering from colorectal 
cancer (0%) or IBD (25%) (P < 0.05). B. adolescentis was 
only found in colorectal cancer patients (5 out of  21; 
24%). The occurrence of  B. bifidum was slightly higher 
in the mucosa of  IBD patients (75%) than in those with 
colorectal cancer (52%) or diverticulitis (44%) although the 
differences were not statistically signifi cant.
Quantitative assessment of the bifi dobacterial population
The levels of  total bifidobacteria as well as those of  
the most widely found Bifidobacterium species or groups 
(B. longum and B. bifi dum) are shown in Table 1.
The levels of  bifi dobacteria in the mucosa samples of  
patients with colorectal cancer or IBD were signifi cantly 
lower (2.02 and 1.05 log Cells/sample, respectively) than 
those observed in diverticulitis patients. The same was 
observed for B. longum while no differences among the 
three groups were found for the other Bifidobacterium 
species tested (B. bifidum). A significantly higher ratio 
between B. longum and total bifidobacteria was also 
observed in samples of  patients with diverticulitis than in 
those with colorectal cancer or IBD (Table 1).
DISCUSSION
Here we studied the bifidobacterial mucosa-associated 
bifi dobacteria in patients with colorectal cancer, diverticulitis 
or IBD. The qualitative bifidobacterial composition of  
the distal colon mucosa was characterized and the levels 
of  the predominant Bifidobacterium species determined, 
showing a different microbiota composition in the different 
disease groups tested. The fi ndings obtained using culture-
independent techniques support the hypothesis that 
colorectal bacteria may play a role in the pathogenesis of  
several intestinal diseases. 
Traditionally faecal samples have been used to assess 
the intestinal microbiota but the representativness of  
these to processes in the colon can be criticized. Mucosa-
associated bacteria may be more reflective of  the long 
term milieu in the colon wall and therefore prove to be a 
better indicator of  disease-related microbiota aberrancies, 
as these microorganisms may have a stronger interaction 
with the host cells. 
Only a few studies with mucosal samples have been 
conducted in both healthy individuals and patients[24,25]. 
In this area, the mucosal microbiota of  patients suffering 
infl ammatory conditions such as IBS and IBD is the most 
widely characterized. 
When mucosal samples from patients with IBD were 
analysed and compared with those of  healthy controls, 
lower levels of  bifi dobacteria and higher of  Clostridium and 
Escherichia coli were observed in the former group[18]. In 
addition, reduced levels of  bifi dobacteria in the colorectal 
mucosa of  patients with ulcerative colitis (a manifestation 
of  IBD) have also been reported[26]. In general, our results 
on the occurrence and levels of  total Bifi dobacterium are in 
the range of  those reported by Poxton and co-workers[25] 
in patients with ulcerative colitis. However, our study 
extends these observations to the level of  Bifidobacterium 
species and differences in the species composition which 
may more accurately reflect the intestinal microbiota 
activity. Although the number of  patients included in this 
study is too low to establish fi rm conclusions, our results 
indicate differences in the presence of  B. longum and B. 
animalis among the distal colonic mucosa of  patients with 
different diseases. Also the levels of  B. longum and its ratio 
with regard to the total bifi dobacterial levels were found to 
be different.
Unfortunately, samples from healthy controls were 
not available for comparison but our results indicate 
that the intestinal mucosal microbiota is altered in 
different diseases. Patients with colorectal cancer or IBD 
harbor lower levels of  total bifidobacteria and especially 
B. longum showing a reduced occurrence of  B. longum and 
also B. animalis in their colonic mucosa when compared to 
diverticulitis patients. This may refl ect the long time frame 
involved with colon cancer development. It may also suggest 
that microbiota screening procedures could be developed to 
Table 1  Levels of total bifi dobacteria, B. longum, B. bifi dum 
as well as B. longum/total bifi dobacteria ratio in the different 
patient groups  (mean ± SE)
Group                        Log Cells/Sample ratio
Bifi dobacterium B. longum B. bifi dum B. longum/
Bifi dobacterium
Colorectal 
cancer (n = 21)
4.94 ± 0.40a 4.05 ± 0.37a 3.21 ± 0.28 0.21 ± 0.06a
Diverticulitis 
(n = 9)
6.96 ± 0.26a 6.76 ± 0.35a 2.95 ± 0.42 0.66 ± 0.14a
IBD (n = 4) 5.91 ± 0.72a 4.49 ± 0.85a 3.68 ± 0.66 0.07 ± 0.03a
        a         a        NS         a
aP < 0.05.
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Figure 1  Occurrence (%) of the different bifi dobacterial groups and species in the 
analysed mucosal samples (n = 34). Signifi cantly higher than the other two patient 
groups (aP < 0.05).
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identify potential aberrancies that may be correlated to the 
colorectal cancer risk of  the subject. 
A thorough knowledge of  the gut microbiota 
composition will offer a basis for future interventional 
studies to improve colonic health. To this regard, probiotic 
or prebiotic intervention has been suggested to be 
benefi cial in the prevention and treatment of  colon cancer 
by different mechanisms[26]. A specifi c probiotic has been 
found to modulate the expression of  genes involved in 
cell growth and differentiation in the intestinal mucosa of  
human volunteers[27]. Probiotics have also been successfully 
applied in patients with IBD[28,29] or diverticulitis[30].
Several studies indicate that aberrancies in faecal 
microbiota are present in different diseases, and our results 
strengthen those studies with colonic mucosa data. These 
results indicate that the mucosa-associated microbiota 
is disturbed in different diseases, as indicated by the 
observed alterations in the bifi dobacterial microbiota. This 
may imply a role of  the microbiota in the pathogenesis of  
different diseases requiring further characterization in both 
patients and subjects at risk of  developing specifi c diseases. 
Characterizing the differences in mucosa-associated 
bacteria more accurately will increase our understanding of  
their role in health and disease and it may provide targets 
for intervention and further development in the disease 
risk reduction area.
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 COMMENTS
Background
The microbiota present in the human gastrointestinal tract has a signifi cant infl uence 
on our health and well-being. Major dysfunctions of the gastrointestinal tract are 
thought to be related to disturbances or aberrancies of the intestinal microbiota. 
Many diseases and their prevention can thus be linked to the microbiota in the gut. 
Demonstration of this has stimulated research on the composition and function of the 
microbiota. A thorough knowledge of the gut microbiota composition will offer a basis 
for future interventional studies to improve colonic health. 
Research frontiers
Major dysfunctions of the gastrointestinal tract are thought to be related to 
disturbances or aberrancies of the intestinal microbiota. Such aberrancies have been 
identifi ed in atopic disease, rheumatoid arthritis, juvenile chronic arthritis, ankylosing 
spondylitis, irritable bowel syndrome (IBS), infl ammatory bowel disease (IBD), colon 
cancer and diverticulitis patients. Mucosal surfaces are the major sites of contact 
with external agents including the members of the intestinal microbiota. However, 
our knowledge on gut microbiota is mainly based on the assessment of faeces and 
are therefore hindered by the fact that the microbes found will mainly represent the 
microbiota in the lumen of the sigmoid colon, while the composition of the intestinal 
microbiota may differ between the lumen and the mucosa. For more accurate 
information on the population elsewhere in the intestine, samples should preferably 
be taken by endoscopies or during surgery. Here we studied the bifidobacterial 
mucosa-associated bifidobacteria in patients with colorectal cancer, diverticulitis 
or IBD. The qualitative bifi dobacterial composition of the distal colon mucosa was 
characterized and the levels of the predominant Bifi dobacterium species determined, 
showing a different microbiota composition in the different disease groups tested.
Innovations and breakthroughs
The intestinal mucosal microbiota has been reported to be altered in patients 
with different diseases. Specifically, reduced levels of intestinal bifidobacteria 
have been observed in some diseases. This study extends these observations to 
the level of Bifi dobacterium species and differences in the species composition 
which may more accurately refl ect the intestinal microbiota activity. The results 
of this study show that aberrancies in mucosa associated microbiota are present 
in different intestinal diseases. This may indicate a role of the microbiota in the 
pathogenesis of these diseases. 
Applications 
The results of this study may indicate a role of the microbiota in the pathogenesis 
of different diseases requiring further characterization in both patients and subjects 
at risk of developing specifi c diseases. Characterizing the differences in mucosa-
associated bacteria more accurately will increase our understanding of their 
role in health and disease and it may provide targets for intervention and further 
development in the disease risk reduction area.
Terminology
We think the terminology used in this article will be easily understandable for the 
readers.
Peer review
The authors qualitatively and quantitatively analyzed the bifi dobacterial microbiota 
in colonic mucosa of patients with colorectal cancer, diverticulitis and infl ammatory 
bowel disease and provide an interesting fi nding that the component and level of 
microbiota differed among these three groups. The study provides some relevant 
information regarding the quantitative and qualitative presence of bifi dobacterial 
microbiota in the colon of patients with colon cancer, diverticulitis and infl ammatory 
bowel disease.
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